| Bioactivity | Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody. |
| Invitro | Ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells[1]. Ustekinumab is a human IgG1 kappa (κ) monoclonal antibody against the IL-12/IL-23 p40 subunit that prevents its interaction with IL-12Rβ1, thereby blocking subsequent signaling. The FcRn affinities at pH 6.0 fell in a narrow range for all 11 antibodies. The equilibrium dissociation constant (KD) is calculated relative to Ustekinumab (Ustekinumab=1.0)[2]. |
| Name | Ustekinumab |
| CAS | 815610-63-0 |
| Molar Mass | 145625.97 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Montepaone M, et al. Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis. Open Access Rheumatol. 2014 Feb 20;6:7-13. [2]. Schoch A, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002. |